|
業務類別
|
Biotechnology |
|
業務概覽
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States. |
| 公司地址
| 730 Third Avenue, 9th Floor, New York, NY, USA, 10017 |
| 電話號碼
| +1 781 419-1400 |
| 傳真號碼
| +1 781 419-1420 |
| 公司網頁
| https://www.syndax.com |
| 員工數量
| 277 |
| Mr. Michael A. Metzger |
Director and Chief Executive Officer |
美元 754.30K |
30/04/2026 |
| Mr. Keith A. Goldan |
Chief Financial Officer and Principal Accounting Officer |
美元 516.90K |
30/04/2026 |
| Mr. Luke J. Albrecht |
General Counsel and Secretary |
美元 496.90K |
30/04/2026 |
| Dr. Neil Gallagher, M.D.,PhD |
President and Head of Research and Development |
-- |
16/05/2025 |
| Mr. Steven Closter |
Chief Commercial Officer |
美元 485.30K |
30/04/2026 |
| Dr. Nicholas A.J. Botwood |
Head, Research and Development and Chief Medical Officer |
美元 345.68K |
30/04/2026 |
|
|
| Mr. Dennis G. Podlesak |
Chairman of the Board |
30/04/2026 |
| Mr. Keith A. Katkin |
Independent Director |
30/04/2026 |
| Mr. Pierre Legault, C.P.A.,M.B.A. |
Independent Director |
30/04/2026 |
| Mr. Michael A. Metzger |
Director and Chief Executive Officer |
30/04/2026 |
| Dr. Martin H. Huber, M.D. |
Independent Director |
30/04/2026 |
| Ms. Jennifer Ann Jarrett |
Independent Director |
30/04/2026 |
| Dr. Aleksandra Rizo, M.D.,PhD |
Independent Director |
30/04/2026 |
|
|
|
|
